ArticleBiomedica : revista del Instituto Nacional de Salud2025
Strong antibody reactivity to HIV-1 synthetic peptides in seropositive indigenous Warao people
Article in Biomedica : revista del Instituto Nacional de Salud, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrevious studies have described an epidemic of HIV-1 in the indigenous Warao population living in the Orinoco Delta, Venezuela. The Warao face extraordinary challenges amid of their ongoing HIV-1 epidemic, the highest reported HIV-1 prevalence in indigenous groups (9.6%) in South America.
objectiveTo investigate the antibody reactivity to HIV-1 synthetic peptides in seropositive individuals, with a particular focus on the indigenous Warao population from Venezuela. MATERIALS AND
methodsThe HIV-1 Pol region from infected patients' isolates was amplified, sequenced, and analyzed using phylogenetic tools. Custom-designed synthetic peptides were derived from conserved regions of HIV-1 glycoproteins 41 and 120, based on reference sequences. Multiple antigen blot assays were used to evaluate the presence of antibodies against synthetic peptides.
resultsThe most frequent HIV-1 subtype was B, the most common in Venezuela, although some individuals were infected with subtype A1. Distinct patterns of reactivity to synthetic peptides were observed between the sera of the general population and the Warao population; the sera of the latter exhibited a high intensity of peptide recognition.
conclusionsThe use of synthetic peptides, coupled with the robust performance of multiple antigen blot assays, enriches our understanding of antibody responses in different HIV-1-infected populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.